NO934320L - T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer - Google Patents

T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Info

Publication number
NO934320L
NO934320L NO934320A NO934320A NO934320L NO 934320 L NO934320 L NO 934320L NO 934320 A NO934320 A NO 934320A NO 934320 A NO934320 A NO 934320A NO 934320 L NO934320 L NO 934320L
Authority
NO
Norway
Prior art keywords
immune
cell receptor
therapeutic agents
related diseases
tcr
Prior art date
Application number
NO934320A
Other languages
English (en)
Other versions
NO934320D0 (no
Inventor
Arthur Allen Vandenbark
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of NO934320D0 publication Critical patent/NO934320D0/no
Publication of NO934320L publication Critical patent/NO934320L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Peptider og farmasøytiske sammensetninger omfattende immunogene peptider av en markør T celle reseptor (TCR) karakteristisk for en immun-relatert sykdom som kan forhindre, undertrykke eller behandle sykdommen, er beskrevet. I en foretrukket utførelsesform tilsvarer aminosyresekvensen til peptidet i det minste en del av en komplementårltetsbes-temmende region (CDR) eller en hypervariabel region til TCR. Antistoffer og/eller T celler som er immunologisk reaktive for TCR peptidet som kan forhindre, undertrykke eller behandle en immun- relatert sykdom ved passiv overføring er også beskrevet.
NO934320A 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer NO934320L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70802291A 1991-05-31 1991-05-31
US73561291A 1991-07-16 1991-07-16
PCT/US1992/004492 WO1992021367A1 (en) 1991-05-31 1992-06-01 T cell receptor peptides as therapeutics for immune-related disease

Publications (2)

Publication Number Publication Date
NO934320D0 NO934320D0 (no) 1993-11-29
NO934320L true NO934320L (no) 1994-01-27

Family

ID=27108005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934320A NO934320L (no) 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Country Status (11)

Country Link
EP (1) EP0587735B1 (no)
JP (1) JPH07502977A (no)
AT (1) ATE189230T1 (no)
AU (1) AU674494B2 (no)
CA (1) CA2110055C (no)
DE (1) DE69230612T2 (no)
DK (1) DK0587735T3 (no)
ES (1) ES2144418T3 (no)
GR (1) GR3033318T3 (no)
NO (1) NO934320L (no)
WO (1) WO1992021367A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
EP0674661B1 (en) * 1992-12-18 2003-07-02 Molecular Rx., Inc. Assay and treatment for demyelinating diseases such as multiple sclerosis
GB9308581D0 (en) * 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
WO1994026876A1 (en) * 1993-05-14 1994-11-24 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
ATE213499T1 (de) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
WO1997043411A1 (fr) * 1996-05-10 1997-11-20 Kirin Beer Kabushiki Kaisha Peptides a regions constantes de chaine alpha de recepteur des cellules t, leurs procedes de production et leur utilisation
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
WO2015145449A2 (en) * 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
RU2138512C1 (ru) * 1989-03-21 1999-09-27 Дзе Иммюн Риспонз Корпорейшн Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
NZ234586A (en) * 1989-07-19 1993-02-25 Arthur Allen Vandenbark Peptide of a t-cell receptor capable of inducing protection from immune-related disease
CA2101065A1 (en) * 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
AU674494B2 (en) 1997-01-02
CA2110055C (en) 2002-08-20
ES2144418T3 (es) 2000-06-16
NO934320D0 (no) 1993-11-29
EP0587735A1 (en) 1994-03-23
EP0587735B1 (en) 2000-01-26
GR3033318T3 (en) 2000-09-29
DE69230612D1 (de) 2000-03-02
DK0587735T3 (da) 2000-09-11
AU2147292A (en) 1993-01-08
JPH07502977A (ja) 1995-03-30
ATE189230T1 (de) 2000-02-15
DE69230612T2 (de) 2000-06-21
EP0587735A4 (en) 1995-05-03
WO1992021367A1 (en) 1992-12-10
CA2110055A1 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
NO934320L (no) T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer
NO920252D0 (no) T celle-reseptor peptider som legemiddel for autoimmun ogmalign sykdom
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
EP0330227A3 (en) Derivatives of soluble t-4
NO941986L (no) Anti-kreft immunoterapeutisk vektorkonstruksjoner
Cronkite et al. Mechanism of protective action of glutathione against whole body irradiation.
ES8501980A1 (es) Un procedimiento para la preparacion de una vacuna contra picornavirus.
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
CA2399676A1 (en) Pharmacologically active antiviral peptides and methods of their use
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
CA2254082A1 (en) Metastatic colorectal cancer vaccine
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
AU3991899A (en) Verotoxin b subunit for immunization
Billingham et al. “Adoptive” immunization of animals against skin isografts and its possible implications
AU8501191A (en) Cross-reactive influenza a immunization
Silverman et al. Enterically induced regulation of systemic immune responses. I. Lymphoproliferative responses in mice suppressed by ingested antigen.
SE9402332D0 (sv) Igf-1
James In vivo and in vitro Effect of Anti-lymphocytic IgG on Sensitized Spleen Cells
北原糺 Molecular mechanisms of vestibular compensation
Sugita et al. The Experimental Study of Herpes Simplex Virus Infection in the Facial Nerve
Oderfeld-Nowak et al. Time Course of Trophic Responses of Astrocytes in Rat Hippocampus Induced by Trimethyltin Intoxication: an Immunocytochemical Study
Henahan et al. AIDS vaccines: immune manipulation achieved but doubts remain